Finally, based on the target capability of HA with CD44 over‐expressed in cancer cells, the AHA@MnP/siPD‐L1 NPs exhibited significant accumulation at tumor sites with good biosafety and demonstrated potent antitumor effects against 4T1 tumors. This evidence concerns the gene CD44 and cancer.